<DOC>
	<DOCNO>NCT01474941</DOCNO>
	<brief_summary>The primary purpose trial evaluate safety tolerability , pharmacokinetics pharmacodynamics , multiple oral dos PF-04620110 modified-release formulation .</brief_summary>
	<brief_title>A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects</brief_title>
	<detailed_description>To evaluate safety tolerability , pharmacokinetics ( PK ) , pharmacodynamics , multiple oral dos PF-04620110 modified-release formulation .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 27 35 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Multiple Dose Study Overweight Healthy Subjects Body Weight Modified-Release Formulation</keyword>
</DOC>